Atherosclerosis
Volume 192, Issue 2 , Pages 291-297 , June 2007

Ghrelin inhibits angiotensin II-induced migration of human aortic endothelial cells

Received 22 February 2006 ,Revised 13 July 2006 ,Accepted 20 July 2006.

References 

  1. Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormone releasing acylated peptide from stomach. Nature. 1999;402:656–660
  2. Koijama M, Kangawa K. Ghrelin: structure and function. Physiol Rev. 2005;85:495–522
  3. Papotti M, Ghe C, Cassoni P, et al. Growth hormone secretagogue binding sites in peripheral human tissues. J Clin Endocrinol Metab. 2000;85:3803–3807
  4. Bodart V, Bouchard JF, McNicoll N, et al. Identification and characterization of a new growth hormone-releasing peptide receptor in the heart. Circ Res. 1999;85:796–808
  5. Enomoto M, Nagaya N, Uematsu M, et al. Cardiovascular and hormonal effects of subcutaneous administration of ghrelin, a novel growth hormone-releasing peptide, in healthy humans. Clin Sci. 2003;105:431–435
  6. Nagaya N, Kojima M, Uematsu M, et al. Hemodynamic and hormonal effects of human ghrelin in healthy volunteers. Am J Physiol Regulatory. 2001;280:R1483–R1487
  7. Nagaya N, Miyatake K, Uematsu M, et al. Hemodynamic, renal, and hormonal effects of ghrelin infusion in patients with chronic heart failure. J Clin Endocrinol Metab. 2001;86:5854–5859
  8. Ghigo E, Arvat E, Broglio F, et al. Endocrine and nonendocrine activities of growth hormone secretagogues in humans. Horm Res. 1999;51:9–15
  9. Okumura H, Nagaya N, Enomoto M, et al. Vasodilatory effect of ghrelin, an endogenous peptide from the stomach. J Cardiovasc Pharmacol. 2002;39:779–783
  10. Poykko SM, Kellokoski E, Horkko S, et al. Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes. Diabetes. 2003;52:2546–2553
  11. Li WG, Gavrila D, Liu X, et al. Ghrelin inhibits proinflammatory responses and nuclear factor-{kappa}B activation in human endothelial cells. Circulation 2004;109:2221–2226.
  12. Santiemma V, Beligotti F, Magnanti M, et al. Endothelin-1 stimulates deoxyribonucleic acid synthesis and contraction in testicular peritubular myoid cells. Biol Reprod. 1996;54:583–590
  13. Rossi F, Ferraresi A, Romagni P, Silvestroni L, Santiemma V. Angiotensin II stimulates contraction and growth of testicular peritubular myoid cells in vitro. Endocrinology. 2002;143:3096–3104
  14. Albini A, D’Agostini F, Giunciuglio D, et al. Inhibition of invasion, gelatinase activity, tumor take and metastasis of malignant cells by N-acetylcysteine. Int J Cancer. 1995;61:121–129
  15. Rossi F, Zappa C, Ferraresi A, Santiemma V. Adrenomedullin inhibits angiotensin II-induced contraction in human aortic smooth muscle cells. Regul Pept. 2006;133:155–159
  16. Baldanzi G, Filigheddu N, Cutrupi S, et al. Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 and PI 3-kinase/AKT. J Cell Biol. 2002;23:1029–1037
  17. Malagon MM, Luque RM, Ruiz-Guerrero E, et al. Intracellular signaling mechanisms mediating ghrelin-stimulated growth hormone release in somatotropes. Endocrinology. 2003;144:5372–5380
  18. Wiley KE, Davenport AP. Comparison of vasodilators in human internal mammary artery: ghrelin is a potent physiological antagonist of endothelin-1. Br J Pharmacol. 2002;136:1146–1152
  19. Katugampola SD, Pallikaros Z, Davenport AP. [125I-His(9)]-ghrelin, a novel radioligand for localizing GHS orphan receptors in human and rat tissue: up-regulation of receptors with athersclerosis. Br J Pharmacol. 2001;134:143–149
  20. Goetze S, Bungenstock A, Czupalla C, et al. Leptin induces endothelial cell migration through Akt, which is inhibited by PPARgamma-ligands. Hypertension. 2002;40:748–754
  21. Kahn J, Mehraban F, Ingle G, et al. Gene expression profiling in an in vitro model of angiogenesis. Am J Pathol. 2000;156:1887–1900
  22. Favot L, Keravis T, Holl V, Le Bec A, Lugnier C. VEGF-induced HUVEC migration and proliferation are decreased by PDE2 and PDE4 inhibitors. Thromb Haemost. 2003;90:334–343
  23. Newby AC, Zaltsman AB. Molecular mechanisms in intimal hyperplasia. J Pathol. 2000;190:300–309
  24. Morales-Ruiz M, Fulton D, Sowa G, et al. Vascular endothelial growth factor-stimulated actin reorganization and migration of endothelial cells is regulated via the serine/threonine kinase Akt. Circ Res. 2000;86:892–896
  25. Netherton SJ, Maurice DH. Vascular endothelial cell cyclic nucleotide phosphodiesterases and regulated cell migration: implications in angiogenesis. Mol Pharmacol. 2005;67:263–272
  26. Iwasaki T, Chen JD, Kim JP, Wynn KC, Woodley DT. Dibutyryl cyclic AMP modulates keratinocyte migration without alteration of integrin expression. J Invest Dermatol. 1994;102:891–897
  27. Edin ML, Howe AK, Juliano RL. Inhibition of PKA blocks fibroblast migration in response to growth factors. Exp Cell Res. 2001;270:214–222
  28. Ydrenius L, Molony L, Ng-Sikorski J, Andersson T. Dual action of cAMP-dependent protein kinase on granulocyte movement. Biochem Biophys Res Commun. 1997;235:445–450
  29. Howe AK. Regulation of actin-based cell migration by cAMP/PKA. Biochim Biophys Acta. 2004;1692:159–174
  30. Kawasaki H, Springett GM, Mochizuki N, et al. A family of cAMPbinding proteins that directly activate Rap1. Science. 1998;282:2275–2279
  31. de Rooij J, Zwartkruis FJ, Verheijen MH, et al. Epac is a Rap1 guaninenucleotide-exchange factor directly activated by cyclic AMP. Nature. 1998;396:474–477
  32. Bos JL. EPAC: a new cAMP targhet and new avenues in cAMP research. Nat Rev Mol Cell Biol. 2003;4:733–738
  33. Oh J, Seo DW, Diaz T, et al. Tissue inhibitors of metalloproteinase 2 inhibits endothelial cell migration through increased expression of RECK. Cancer Res. 2004;64:9062–9069
  34. Fujita H, Fukuhara S, Sakurai A, et al. Local activation of Rap1 contributes to directional vascular endothelial cell migration accompanied by extension of microtubules on which RAPL, a Rap1-associating molecule, localizes. Biol Chem. 2005;280:5022–5031
  35. Utsunomiya H, Nakamura M, Kakudo K, Inagami T, Tamura M. Angiotensin II AT2 receptor localization in cardiovascular tissues by its antibody developed in AT2 gene-deleted mice. Regul Pept. 2005;126:155–161
  36. Pueyo ME, N’Diaye N, Michel JB. Angiotensin II-elicited signal transduction via AT1 receptors in endothelial cells. Br J Pharmacol. 1996;118:79–84
  37. Cai M, Zhang H, Hui R. Single chain Fv antibody against angiopoietin-2 inhibits VEGF-induced endothelial cell proliferation and migration in vitro. Biochem Biophys Res Commun. 2003;309:946–951
  38. Benndorf R, Boger RH, Ergun S, Steenpass A, Wieland T. Angiotensin II type 2 receptor inhibits vascular endothelial growth factor-induced migration and in vitro tube formation of human endothelial cells. Circ Res. 2003;93:438–447
  39. Desideri G, Bravi MC, Tucci M, et al. Angiotensin II inhibits endothelial cell motility through an AT1-dependent oxidant-sensitive decrement of nitric oxide availability. Arterioscler Thromb Vasc Biol. 2003;23:1218–1223
  40. Montiel M, de la Blanca EP, Jimenez E. Angiotensin II induces focal adhesion kinase/paxillin phosphorylation and cell migration in human umbilical vein endothelial cells. Biochem Biophys Res Commun. 2005;327:971–978

PII: S0021-9150(06)00443-6

doi: 10.1016/j.atherosclerosis.2006.07.021

Atherosclerosis
Volume 192, Issue 2 , Pages 291-297 , June 2007

Article Tools

* Image Usage & Resolution